| Name | Atorvastatin hemicalcium salt |
| Description | Atorvastatin hemicalcium salt (Atorvastatin Calcium) is an HMG-CoA reductase inhibitor with oral activity. Atorvastatin hemicalcium salt is used to lower cholesterol. |
| Cell Research | Briefly, SV-SMC from 5 different patients are seeded into 24-well cell culture plates at a density of 1×104?cells per well in full growth medium. Cells are incubated overnight and then quiesced in serum free medium for 3 days before transfer to full growth medium (10% FCS) containing 5 different statins (simvastatin, atorvastatin, fluvastatin, lovastatin, and pravastatin)at a range of concentrations. All statins are tested on cells from each individual patient. Medium and drugs are replaced after 2 days, and viable cell numbers are determined in triplicate wells after 4 days using Trypan Blue and a hemocytometer. The increase in cell number is calculated by subtracting the starting cell number (day 0) from the final cell number (day 4). Data are then normalized to control values (no statin) to correct for differences in proliferation rates between cells from different patients. |
| In vitro | METHODS: HCT-116, A375, MIA PaCa-2 and BJ hTERT cells were treated with CX5461 (0-10 µM) for 96 h and cell viability was measured by CyQUANT assay.
RESULTS: Antiproliferative dose-response assessment of HCT-116, A375, and MIA PaCa-2 cell lines yielded EC50s of 167, 58, and 74 nmol/L, respectively. the EC50 of the BJ-hERT normal cell line was approximately 5000 nmol/L. [1]
METHODS: CaSki cells were treated with CX5461 (1-5 µM) for 24-72 h, and the expression levels of target proteins were detected by Western Blot.
RESULTS: After CX5461 treatment, LC3I was completely converted to LC3II, while p62 expression was reduced. densitometric analysis of LC3I and LC3II bands showed that the LC3II:LC3I ratio was significantly increased after 72 h of CX5461 treatment. [2] |
| In vivo | METHODS: To assay antitumor activity in vivo, CX5461 (50 mg/kg, 50 mmol/L NaH2PO4 pH 4.5) was administered orally to mice bearing MIA PaCa-2 or A375 xenografts once daily or every three days for 32 days.
RESULTS: CX5461 showed a significant MIA PaCa-2 TGI equal to 69% on day 31. Similarly, CX5461 showed a significant A375 TGI with a TGI of 79% on day 32. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (43.28 mM)
|
| Keywords | Autophagy | Ferroptosis | inhibit | Inhibitor | Atorvastatin hemicalcium salt | Atorvastatin | HMG-CoA Reductase (HMGCR) | CI 981 | CI981 |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Paeonol | L-Cystine | Naringin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
